VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

NCRI 2018 | ctDNA measurement via liquid biopsy: improving cancer detection and diagnosis

Pierre-Jean Lamy
NCRI 2018
Lung Cancer Non-Small Cell Lung Cancer

Pierre-Jean Lamy, PharmD, PhD, of the Medical Institute of Genomic Analysis, Montpellier, France, discusses recent developments around the use of circulating tumor (ct)DNA as a biomarker, providing a non-invasive substitute for biopsies. Speaking at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK, Dr Lamy discusses the limitations, next-steps and exciting new developments in the application of ctDNA in the detection and diagnosis of cancer.

More from Pierre-Jean Lamy

3:07
Future uses of ctDNA measurements: changing the treatment landscape
Pierre-Jean Lamy

Related Videos

1:49
Building a clinical research platform to capture and leverage data from cancer care in Germany
Frank Griesinger
3:07
Future uses of ctDNA measurements: changing the treatment landscape
Pierre-Jean Lamy
0:45
How to discuss immunotherapy as a treatment option with lung cancer patients
Rolf Stahel
2:43
Clinical factors in the selection of patients for first-line immunotherapy of lung cancer
Benjamin Besse

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals